title: [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
abstract: Prostatic neuroendocrine (NE) carcinoma is a rare disease with a poor prognosis because of its rapid progression and the androgen-independent characteristic, for which no successful therapy is available presently. We report a case of NE differentiated prostate cancer, which was diagnosed as adenocarcinoma initially and progressed with NE differentiation during the combined androgen blockade therapy.
authors.affiliation: The Department of Urology, Osaka City University Graduate School of Medicine.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Kitamoto
authors.forename: Teruaki
authors.initials: T
authors.lastname: Hayashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tamada
authors.forename: Kazuyosi
authors.initials: K
authors.lastname: Ezaki
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kawashima
authors.forename: Kazunobu
authors.initials: K
authors.lastname: Sugimura
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatani
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*
chemical_list: D000726:Androgen Antagonists